NICE says no to Celgene's Vidaza for leukaemia
This article was originally published in Scrip
Celgene's Vidaza (azacitidine) would not be a cost-effective use of NHS resources treating myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia and acute myeloid leukaemia, says NICE, the health technology appraisal body for England and Wales.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.